Alzheimer Hastalığı'nın Maliyet Etkililik Analizi

Abstract

Objective: Chronic diseases, comparing to the other type of diseases, consume most of the resources in the health systems. Alzheimer's Disease (AD) is a chronic cerebral disorder and is the most common type of dementia. The purpose of this research is to analyze cost effectiveness according to stages of AD from the perspective of Social Security Institution (SSI) and the society and to determine the burden of the disease on the country's budget. Material and Methods: Using the Markov Model, three parameters were calculated in the study: lifelong cost, average survival time (ST) (year), and quality adjusted life year (QALY). Results: According to the cost-effectiveness analysis, treatment in early-stage causes additional ₺ 41.237,55 cost and provides additional 1.10 QALY comparing to the treatment in severe-stage. Likewise, treatment in moderate-stage causes an additional ₺ (-) 40.439,83 cost and provides additional 1.07 QALY comparing to the treatment in severe-stage. According to the results of the budget impact analysis made from the SSI perspective for AD, 0.66% of the total health expenditures were spent on the treatment of this disease. The social cost of AD was estimated as ₺ 14.462.457,106. Conclusion: The study was concluded that early and moderate-stage treatment of AD is cost-effective compared to severestage treatment. As a result of the study, it was revealed that the social and economic costs increased and the quality of life of the patients decreased in the progress stages of AD. The results of this study are thought to be important in terms of the assessment of the economic impact of AD in the Turkey.